Low expression of XIAP-associated factor 1 in human colorectal cancers

Tian Le Ma1, Pei Hua Ni, Jie Zhong

  • 1Department of Gastroenterology, Ruijin Hospital, Shanghai Second Medical University, Shanghai, China. mtla@etang.com

Abstract

Insights

XAF1 expression is low in colorectal cancer (CRC) tissues and circulation, suggesting a role in malignancy. Combining XAF1 with other markers significantly improves CRC diagnosis rates.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The inhibitors-of-apoptosis proteins (IAP) family includes eight human homologs, with X-linked IAP (XIAP) being the most potent.
  • XIAP-associated factor 1 (XAF1) is a novel XIAP-binding protein that downregulates XIAP's caspase-inhibiting activity.
  • XAF1 exhibits low or undetectable expression in many cancer cell lines, indicating its potential role in cancer development.

Purpose of the Study:

  • To investigate XAF1 expression in human colorectal cancers (CRC) in vitro and in vivo.
  • To assess the potential of XAF1 as a novel tumor marker for CRC.

Main Methods:

  • XAF1 mRNA expression was analyzed in four human colon cancer cell lines using reverse transcriptase-polymerase chain reaction (RT-PCR).
  • XAF1 tissue expression was evaluated in 70 CRC patient samples.
  • XAF1 concentrations in peripheral circulation were measured in the same 70 patients, alongside three traditional cancer-associated antigens.

Main Results:

  • XAF1 mRNA was detectable in three of four colon cancer cell lines, with Colo205 showing the highest expression.
  • XAF1 tissue expression was significantly lower in primary CRC compared to benign colorectal tumors (P < 0.01).
  • Circulating XAF1 levels were lower in CRC patients than in benign tumor patients, but this difference was not statistically significant (P > 0.05).

Conclusions:

  • Low XAF1 expression in tumor tissue and peripheral circulation may contribute to the malignant behavior of CRC.
  • A four-parameter assay integrating XAF1 relative expression with three traditional tumor biomarkers significantly enhanced CRC diagnostic rates.